Ultra Market Research | Europe Obesity Drugs Market
Europe Obesity Drugs Market
Report ID : 787
Category : Pharmaceuticals,Europe
No Of Pages : 127
Published on: October 2024
Status: Published
Format :
Key Question Answer
Global Market Outlook
In-depth analysis of global and regional trends
Analyze and identify the major players in the market, their market share, key developments, etc.
To understand the capability of the major players based on products offered, financials, and strategies.
Identify disrupting products, companies, and trends.
To identify opportunities in the market.
Analyze the regional penetration of players, products, and services in the market.
Comparison of major players financial performance.
Evaluate strategies adopted by major players.
Recommendations
Introduction The Europe obesity drugs market is experiencing significant growth as obesity rates rise and healthcare systems respond with pharmacological solutions to manage weight-related health risks. Obesity drugs are therapeutic medications prescribed to assist with weight reduction for individuals struggling to achieve effective results through diet and exercise alone. In Europe, anti-obesity drugs include various prescription options like appetite suppressants, GLP-1 receptor agonists, and fat absorption inhibitors, tailored to support weight management and reduce comorbidities associated with obesity. Driven by increasing healthcare expenditure and a proactive healthcare environment, the demand for obesity medications in Europe has steadily expanded, reaching significant market size. Current market trends in Europe reflect a growing focus on personalized and minimally invasive therapies, positioning the region as a key player in the global obesity treatment market.
List of Market Players Novo Nordisk (Denmark) Sanofi (France) Roche (Switzerland) AstraZeneca (United Kingdom) GlaxoSmithKline (United Kingdom) Merck & Co. (Germany) Boehringer Ingelheim (Germany) Pfizer (United States, with a significant presence in Europe) Eli Lilly (United States, with operations in Europe) Takeda Pharmaceuticals (Japan, with a European division) Orion Corporation (Finland) Helsinn Healthcare (Switzerland) Ipsen Pharma (France) Amgen (United States, active in Europe) Recordati (Italy)
Drivers 1. Rising obesity prevalence in Europe fuels the demand for effective weight management drugs, prompting more people to seek pharmacological solutions for weight loss. 2. Growing awareness of obesity's link to chronic diseases, such as diabetes and cardiovascular disorders, encourages early treatment with obesity medications. 3. Increasing healthcare expenditure across Europe supports greater access to obesity drugs, especially as governments aim to alleviate the economic burden of obesity-related health issues. 4. Regulatory support and favorable reimbursement policies in some European countries make obesity medications more accessible to a larger patient population. 5. Research and development activities focusing on safer and more effective obesity drugs, particularly GLP-1 receptor agonists, drive the innovation in obesity treatment. 6. The presence of well-established pharmaceutical companies with substantial R&D budgets accelerates advancements and introduces more efficient, targeted obesity treatments.
Restraints 1. The high cost of some obesity drugs, particularly newer medications, limits accessibility for lower-income populations, affecting market penetration. 2. Side effects associated with long-term use of anti-obesity drugs, such as gastrointestinal or cardiovascular complications, deter some patients and healthcare providers. 3. Stringent regulatory requirements for drug approval in Europe create challenges for new obesity drugs to enter the market quickly. 4. Social stigma and reluctance around using medication for weight loss can result in low patient compliance, impacting market growth. 5. Limited effectiveness of some obesity drugs for achieving sustained weight loss hinders widespread adoption and results in patient dissatisfaction. 6. Competition from alternative weight management methods, such as bariatric surgery and non-pharmaceutical approaches, challenges market growth.
Opportunity 1. Expanding access to healthcare services in Eastern Europe and rural regions across the continent offers opportunities for market expansion. 2. Ongoing advancements in personalized medicine open new avenues for customized obesity treatments, targeting individual metabolic and genetic profiles. 3. The integration of digital health and wearable technology into obesity management offers a comprehensive approach, allowing patients to track their progress and engage with their treatment actively. 4. Growing demand for minimally invasive treatment options drives the development of more convenient and tolerable weight management drugs. 5. Partnerships with digital health providers enable the pharmaceutical industry to reach a broader audience and offer telemedicine consultations and support. 6. Increasing investments in research focused on dual-acting medications that address both obesity and diabetes create an opportunity for breakthrough drug development.
Trend The Europe obesity drugs market is increasingly focused on personalized medicine, leveraging genetic insights and individual health data to optimize weight loss treatment. This trend toward precision therapies is transforming how healthcare providers approach obesity treatment, tailoring drugs to specific patient profiles based on metabolic, hormonal, and lifestyle factors. Another emerging trend is the use of GLP-1 receptor agonists, which not only aid in weight loss but also provide benefits for managing Type 2 diabetes, making them attractive for patients dealing with both conditions. Digital health tools are becoming integral to obesity management, with mobile applications and wearables facilitating better patient engagement and compliance. Furthermore, there is a growing preference for combination therapies, where anti-obesity drugs are prescribed alongside lifestyle interventions and behavioral support, addressing obesity holistically. This comprehensive approach reflects a shift in the European market toward sustainable, long-term solutions for weight management rather than short-term fixes.
Key Target Audience Hospitals and Weight Loss Clinics Pharmaceutical Distributors and Retail Pharmacies Insurance Providers and Healthcare Policy Makers Public Health Agencies and Regulators Healthcare Professionals and Specialists Academic and Research Institutes
FAQs about the Europe Obesity Drugs Market
It is a market comprising various prescription drugs used for weight loss and obesity management in European countries.
Growing obesity rates, increasing awareness of obesity-related diseases, and supportive healthcare policies are key drivers.
Common drugs include GLP-1 receptor agonists, appetite suppressants, and fat absorption inhibitors.
While some drugs are costly, there are more affordable generic alternatives and coverage options in certain countries.
Trends include a shift toward personalized medicine, the use of digital health tools, and the development of combination therapies.
1. Introduction 1.1 Report Description 1.2 Research Methodology 1.2.1 Data Mining 1.2.2 Market Modeling and Forecasting 1.2.3 Data Validation 1.2.4 Industry Analysis 2. Market Dashboard 3. Market Overview 3.1 Market Definition and Scope 3.2 Market Segmentation 3.2.1 By Drug Type 3.2.2 By Application 3.2.3 By Distribution Channel 3.2.4 By Administration Route 3.3 Market Dynamics 3.3.1 Drivers 3.3.2 Restraints 3.3.3 Opportunities 3.3.4 Challenges 4. Europe Obesity Drugs Market by Drug Type 4.1 Introduction 4.2 Market Size and Growth Rate by Drug Type (2024-2030) 4.2.1 Appetite Suppressants 4.2.1.1 Anorexiants 4.2.1.2 Serotonin Agonists 4.2.1.3 Others 4.2.2 Fat Absorption Inhibitors 4.2.2.1 Lipase Inhibitors 4.2.2.2 Enzyme Blockers 4.2.3 GLP-1 Receptor Agonists 4.2.3.1 Short-acting GLP-1 Drugs 4.2.3.2 Long-acting GLP-1 Drugs 4.2.3.3 Others 4.2.4 Combination Therapy Drugs 4.2.5 Herbal Supplements 5. Europe Obesity Drugs Market by Application 5.1 Introduction 5.2 Market Size and Growth Rate by Application (2024-2030) 5.2.1 Clinical Obesity Treatment 5.2.1.1 Severe Obesity 5.2.1.2 Morbid Obesity 5.2.1.3 Others 5.2.2 Lifestyle Weight Management 5.2.2.1 Overweight but not Obese 5.2.2.2 Weight Maintenance 5.2.3 Pediatric Obesity Treatment 5.2.3.1 Childhood Weight Management 5.2.3.2 Adolescent Obesity Control 5.2.3.3 Others 5.2.4 Geriatric Weight Management 5.2.4.1 Cardiovascular Treatments 5.2.4.2 Endocrine Therapy Support 5.2.4.3 Others 6. Europe Obesity Drugs Market by Distribution Channel 6.1 Introduction 6.2 Market Size and Growth Rate by Distribution Channel (2024-2030) 6.2.1 Hospitals 6.2.1.1 Public Hospitals 6.2.1.2 Private Clinics 6.2.1.3 Specialized Centers 6.2.2 Retail Pharmacies 6.2.2.1 Chain Pharmacies 6.2.2.2 Independent Outlets 6.2.3 Online Pharmacies 6.2.3.1 Telemedicine-based Distribution 6.2.3.2 Direct-to-Consumer 7. Europe Obesity Drugs Market by Administration Route 7.1 Introduction 7.2 Market Size and Growth Rate by Administration Route (2024-2030) 7.2.1 Oral 7.2.1.1 Tablets 7.2.1.2 Capsules 7.2.1.3 Others 7.2.2 Injectable 7.2.2.1 Intramuscular 7.2.2.2 Subcutaneous 7.2.3 Transdermal Patches 7.2.3.1 Slow-release Patches 7.2.3.2 Quick-absorbing Patches 8. Competitive Landscape 8.1 Company Profiles 8.1.1 Novo Nordisk (Denmark) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.2 Sanofi (France) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.3 Roche (Switzerland) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.4 AstraZeneca (United Kingdom) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.5 GlaxoSmithKline (United Kingdom) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.6 Merck & Co. (Germany) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.7 Boehringer Ingelheim (Germany) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.8 Pfizer (United States, with a significant presence in Europe) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.9 Eli Lilly (United States, with operations in Europe) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.10 Takeda Pharmaceuticals (Japan, with a European division) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.11 Orion Corporation (Finland) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.12 Helsinn Healthcare (Switzerland) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.13 Ipsen Pharma (France) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.14 Amgen (United States, active in Europe) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 8.1.15 Recordati (Italy) • Business Overview • Product Portfolio • Strategic Developments • Financial Overview 9. List of Tables and Figures Tables Table Europe Obesity Drugs Market Size and Market Share by Drug Type (2024-2030) Table Appetite Suppressants Market Size and Market Share by Sub-type (Anorexiants, Serotonin Agonists, Others) (2024-2030) Table Fat Absorption Inhibitors Market Size and Market Share by Sub-type (Lipase Inhibitors, Enzyme Blockers) (2024-2030) Table GLP-1 Receptor Agonists Market Size and Market Share by Sub-type (Short-acting GLP-1 Drugs, Long-acting GLP-1 Drugs, Others) (2024-2030) Table Combination Therapy Drugs Market Size and Market Share (2024-2030) Table Herbal Supplements Market Size and Market Share (2024-2030) Table Europe Obesity Drugs Market Size and Market Share by Application (2024-2030) Table Clinical Obesity Treatment Market Size and Market Share by Sub-type (Severe Obesity, Morbid Obesity, Others) (2024-2030) Table Lifestyle Weight Management Market Size and Market Share by Sub-type (Overweight but not Obese, Weight Maintenance) (2024-2030) Table Pediatric Obesity Treatment Market Size and Market Share by Sub-type (Childhood Weight Management, Adolescent Obesity Control, Others) (2024-2030) Table Geriatric Weight Management Market Size and Market Share by Sub-type (Cardiovascular Treatments, Endocrine Therapy Support, Others) (2024-2030) Table Europe Obesity Drugs Market Size and Market Share by Distribution Channel (2024-2030) Table Hospitals Market Size and Market Share by Sub-type (Public Hospitals, Private Clinics, Specialized Centers) (2024-2030) Table Retail Pharmacies Market Size and Market Share by Sub-type (Chain Pharmacies, Independent Outlets) (2024-2030) Table Online Pharmacies Market Size and Market Share by Sub-type (Telemedicine-based Distribution, Direct-to-Consumer) (2024-2030) Table Europe Obesity Drugs Market Size and Market Share by Administration Route (2024-2030) Table Oral Administration Market Size and Market Share by Sub-type (Tablets, Capsules, Others) (2024-2030) Table Injectable Administration Market Size and Market Share by Sub-type (Intramuscular, Subcutaneous) (2024-2030) Table Transdermal Patches Market Size and Market Share by Sub-type (Slow-release Patches, Quick-absorbing Patches) (2024-2030) Figures Figure Europe Obesity Drugs Market Size and Growth Rate by Drug Type (2024-2030) Figure Appetite Suppressants Market Growth Rate by Sub-type (2024-2030) Figure Fat Absorption Inhibitors Market Growth Rate by Sub-type (2024-2030) Figure GLP-1 Receptor Agonists Market Growth Rate by Sub-type (2024-2030) Figure Combination Therapy Drugs Market Growth Rate (2024-2030) Figure Herbal Supplements Market Growth Rate (2024-2030) Figure Europe Obesity Drugs Market Size and Growth Rate by Application (2024-2030) Figure Clinical Obesity Treatment Market Growth Rate by Sub-type (2024-2030) Figure Lifestyle Weight Management Market Growth Rate by Sub-type (2024-2030) Figure Pediatric Obesity Treatment Market Growth Rate by Sub-type (2024-2030) Figure Geriatric Weight Management Market Growth Rate by Sub-type (2024-2030) Figure Europe Obesity Drugs Market Size and Growth Rate by Distribution Channel (2024-2030) Figure Hospitals Market Growth Rate by Sub-type (2024-2030) Figure Retail Pharmacies Market Growth Rate by Sub-type (2024-2030) Figure Online Pharmacies Market Growth Rate by Sub-type (2024-2030) Figure Europe Obesity Drugs Market Size and Growth Rate by Administration Route (2024-2030) Figure Oral Administration Market Growth Rate by Sub-type (2024-2030) Figure Injectable Administration Market Growth Rate by Sub-type (2024-2030) Figure Transdermal Patches Market Growth Rate by Sub-type (2024-2030)
The process of market research at Ultra Market Research is iterative in application and usually follows following path. Information from secondary used to build data models, then results from data models are validated from primary participants. Then cycle repeats where, according to inputs from primary participants, additional secondary research is done and new Information is again incorporated into data model. The process continues till desired level of Information is not generated
To calculate the market size, the report considers the revenue generated from the sales of Ultra Market Research providers. The revenue generated from the sales of Ultra Market Research has been calculated through primary and secondary research. The report also presents the key players operating in the Ultra Market Research market across the globe identified through secondary research and a corresponding detailed analysis of the top vendors in the market. The market size calculation also includes distribution channel segmentation determined using secondary sources and verified through primary sources.
Secondary Research
The secondary research source that are typically referred to include, but are not limited to:
Company websites, annual reports, financial reports, broker reports, investor presentations and SEC filings
Internal and external proprietary databases, relevant patent and regulatory databases
National government documents, statistical databases and market reports
News articles, press releases and web-casts specific to the companies operating in the market
The source for secondary research includes but is not limited to: Factiva, Hoovers and Statista
Inner Circle Represents – Stage of Research Process
Middle Circle Represents – Source of Information
Outer Circle Represents – Information Derived from that source
Primary Research We conduct primary interviews on an ongoing basis with industry participants and commentators in order to validate data and analysis. A typical research interview fulfills the following functions:
It provides first-hand Information on the market size, market trends, growth trends, competitive landscape, future outlook etc.
Helps in validating and strengthening the secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves E-mail interactions, telephonic interviews as well as face-to-face interviews for each market, category, segment and sub-segment across geographies
The participants who typically take part in such a process include, but are not limited to:
Industry participants: CEOs, VPs, marketing/ distribution channel managers, market intelligence managers and national sales managers
Purchasing managers, technical personnel, distributors and resellers
Outside experts: Investment bankers, valuation experts, research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry distribution channels
Models Where no hard data is available, we use modeling and estimates in order to produce comprehensive data sets. A rigorous methodology is adopted in which the available hard data is cross referenced with the following data distribution channels to produce estimates:
Demographic data: Population split by segment
Macroeconomic indicators: GDP, etc.
Industry indicators: Expenditure, distribution channel stage & infrastructure, sector growth and facilities.
Data is then cross checked by the expert panel.
2..1 Company Share Analysis Model
Company share analysis is used to derive the size of Europe market. As well as study of revenues of companies for last three to five years also provide the base for forecasting the market size and its growth rate. This model is built in following steps: 2..2 Revenue Based Modeling
Revenue based models can be built in two ways – Top-Down or Bottom-Up irrespective of industry. Market size estimated from company share analysis acts as a validation point for bottom-up approach where as it acts as starting point for top-down approach.
2.1 Research Limitations Inflation is not a part of pricing in this report. Prices of Europe Obesity Drugs Market and its derivatives vary in each region and hence similar revenue ratio does not follow for each individual region. The same price for each distribution channel has been taken into account while estimating and forecasting market revenue Europely. Regional average price has been considered while breaking down this market by application in each region. This report provides market size of Europe Obesity Drugs Market for the past year and forecasts for the next six years. Europe Europe Obesity Drugs Market. Market size is given in terms of revenue. Market revenue is defined in USD Million. Market numbers are given on the basis of different Europe Obesity Drugs Market Market categories. Market size and forecasts for each major application is provided in the context of Europe market. The numbers provided in this report are derived on the basis of demand for Europe Obesity Drugs Market from different application industries in different regions.
